1063406-38-1 Usage
Chemical structure
Contains a benzene ring with a methoxy group and a quinoline ring with a nitro group.
Heterocyclic compound
Presence of a dihydroquinolin-2(1H)-one moiety indicates it belongs to a class of heterocyclic compounds.
Potential applications
May have applications in medicinal chemistry due to the study of quinolin-2-one derivatives for their potential as antiviral, antibacterial, and antitumor agents.
Substitution
The substitution of a methoxybenzyl and nitro group suggests it may have specific biological activities or chemical reactivity.
Drug development
Could be useful in drug development or research due to its potential biological activities and chemical reactivity.
Molecular weight
Approximately 308.32 g/mol (calculated from the molecular formula)
Functional groups
Contains aromatic rings, a nitro group, a methoxy group, and a quinolin-2(1H)-one moiety.
Solubility
Likely soluble in organic solvents such as ethanol, methanol, or dimethyl sulfoxide (DMSO) due to its aromatic and heterocyclic nature.
Stability
May be sensitive to light, heat, or moisture, as many compounds with aromatic and heterocyclic structures are prone to degradation under such conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1063406-38-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,3,4,0 and 6 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1063406-38:
(9*1)+(8*0)+(7*6)+(6*3)+(5*4)+(4*0)+(3*6)+(2*3)+(1*8)=121
121 % 10 = 1
So 1063406-38-1 is a valid CAS Registry Number.
1063406-38-1Relevant articles and documents
QUINOLONE AND TETRAHYDROQUINOLONE AND RELATED COMPOUNDS HAVING NOS INHIBITORY ACTIVITY
-
Page/Page column 42, (2008/12/08)
The present invention features quinolones, tetrahydroquinolines, and related compounds that inhibit nitric oxide synthase (NOS), particularly those that selectively inhibit neuronal nitric oxide synthase (nNOS) in preference to other NOS isoforms. The NOS inhibitors of the invention, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing various medical conditions.
